The round highlights collaboration between Welsh public investment bodies and private investors, with the IIC fund and Development Bank sharing in the round for the first time to scale Welsh tech and life sciences.

Antiverse operates from Cardiff with offices in Boston and Prague, focusing on targets such as GPCRs and ion channels, and combining AI design with rapid lab validation for iterative design-build-test workflows.

Headquartered in Cardiff, Antiverse also has offices in Boston and Prague, and more information is available at antiverse.io.

Leadership and regional support praised the round as a strong endorsement of the technology and Cardiff roots, with regional leaders highlighting innovation and global impact.

Executives and supporters emphasized AI-enabled drug discovery’s strategic value and regional growth, noting scale-up potential, global readiness, and long-term growth as key themes.

Antiverse has secured partnerships with multiple top-20 global pharmaceutical firms and aims to advance its first wholly owned candidates into later-stage preclinical development by 2027 while continuing collaborations.

Challenges ahead include turning computational promise into demonstrable preclinical candidates and regulatory-ready therapies while maintaining partnerships to drive platform adoption.

Antiverse’s AI antibody design platform is being expanded to accelerate its internal therapeutic pipeline and move lead programs toward in vivo efficacy studies, while broadening collaborations across pharma and research partners.

The funding accelerates the antibody drug design platform, enabling faster, more cost-effective discovery across oncology, immunology, and infectious diseases and positioning Antiverse for its next growth phase, including a potential Series B.

The investment will scale Antiverse’s generative AI and machine learning tools to predict, design, and optimize antibody-based drugs, speeding up discovery across oncology, immunology, and infectious disease programmes.

The investment will create five new Welsh jobs and safeguard 19 high-skilled roles, expanding the local team and supporting new IP development.

Antiverse completed a $9.3 million Series A led by Soulmates Ventures, bringing total funding to over $20 million and marking its first institutional growth round beyond seed funding, with support from the Development Bank of Wales and Cardiff Capital Region.